Clinical Trial

Early Commencement of Adjuvant Chemotherapy for Colon Cancer

Study acronym: ECTX
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after surgery compared with conventional commencement after 2weeks for treatment of patients with colon cancer. Detailed goal of study: The primary endpoint: This study is designed to assess whether early commencement of adjuvant chemotherapy improves the 3-year disease-free survival, overall survival and recurrence rate. The secondary endpoint: This study aims to compare short-term cumulative complications between early and conventional commencement of adjuvant chemotherapy after laparoscopic resection of colon cancer. This study will also assess the quality of life and side effects of chemotherapy.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2011-10-26; most recent amendment 2026-02-10.
Status change: Recruiting → Active, Not Recruiting 2020-06-03
Status change: Enrolling by Invitation → Recruiting 2015-01-26
Status change: Not Yet Recruiting → Enrolling by Invitation 2011-11-21
Trial Details
NCT Number NCT01460589
Lead Sponsor Kyungpook National University Hospital
Conditions Colon Cancer
Enrollment 303 participants
Start Date 2013-01-13
Primary Completion 2024-06-19 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-12